| 6605 |
PCSK9 Inhibitor: Effect of Alirocumab on CV Events and Mortality After ACS |
Hanbit Park |
Apr. 08. 22 |
| 6604 |
Landscape of Lipid Management Following an ACS Event |
Choongki Kim |
Apr. 08. 22 |
| 6603 |
How is SAPIEN 3 Valve Design Connected to Clinical Benefit? |
Young-Guk Ko |
Apr. 08. 22 |
| 6602 |
Strategies of IVUS-Guided Left Main PCI with SYNERGY MEGATRON™ BP Stent |
Jeehoon Kang |
Apr. 08. 22 |
| 6601 |
SYNERGY MEGATRON – Advancing Your Large Proximal Vessel Strategy for Improved Outcomes |
Huay Cheem Tan |
Apr. 08. 22 |
| 6600 |
Comparison of 2 Different Paclitaxel-coated Balloons in Coronary In-stent Restenosis: A Randomized Controlled Trial |
Eun-Seok Shin |
Apr. 08. 22 |
| 6599 |
Influence of Baseline HbA1c and Antiplatelet Therapy on 1-year Vein Graft Outcome |
Qiang Zhao |
Apr. 08. 22 |
| 6598 |
Sex Differences in Plaque Characteristics and Myocardial Mass: Implications for Physiologic Significance |
Bon-Kwon Koo |
Apr. 08. 22 |
| 6597 |
Third In-Stent Restenosis in 5 Years - Are We Doing Enough? Role of Intravascular Ultrasound and Lithotripsy in Severely Calcified ISR |
Afif Ashari |
Apr. 08. 22 |
| 6596 |
Emergent Thoracic Endovascular Aortic Repair in Patient With Flying Elephant Trunk After Ascending and Total Arch Replacement |
Andrew Parlautan |
Apr. 08. 22 |
